WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc.]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc.]
[8-K/A 1 f8k102414a1_tianyinpharm.htm AMENDMENT NO. 1 TO CURRENT REPORT]
[8-K/A 1 f8k102414a1_tianyinpharm.htm AMENDMENT NO. 1 TO CURRENT REPORT]
[Schedule 14A x o Check the appropriate box: o o x o o Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of securities to which transaction applies: ____________________________ (3) (4) Proposed maximum aggregate value of transaction: ______________________________________ (5)]
[October 23, 2014 Office of the Chief Accountant 460 Fifth Street N. W. Re : Biostar Pharmaceuticals, Inc. Dear Sirs, Clement C. W. Chan & 44342-0000 DC\81064743.1 EX-16.1 2 ex16-1.htm EX-16.1] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): October 19, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
[October 23, 2014 Office of the Chief Accountant 460 Fifth Street N. W. Re : Biostar Pharmaceuticals, Inc. Dear Sirs, Clement C. W. Chan & 44342-0000 DC\81064743.1 EX-16.1 2 ex16-1.htm EX-16.1] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): October 19, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
[Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today reported that, on October 15, 2014, it received a notice from the NYSE MKT Staff indicating] []
[Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today reported that, on October 15, 2014, it received a notice from the NYSE MKT Staff indicating] []